Compare IPHA & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPHA | PLX |
|---|---|---|
| Founded | 1999 | 1993 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.3M | 207.1M |
| IPO Year | 2014 | 1996 |
| Metric | IPHA | PLX |
|---|---|---|
| Price | $1.50 | $2.55 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $6.67 | N/A |
| AVG Volume (30 Days) | 33.5K | ★ 836.2K |
| Earning Date | 09-17-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | $390.56 | $55.77 |
| Revenue Next Year | $143.06 | N/A |
| P/E Ratio | ★ N/A | $9.46 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.17 | $1.65 |
| 52 Week High | $2.71 | $3.19 |
| Indicator | IPHA | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 42.44 |
| Support Level | $1.36 | $2.21 |
| Resistance Level | $1.57 | $2.75 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 40.74 | 19.67 |
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.